Clinical trial
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
NCT06055465
Study timeline
Study start (actual)2024-02-28Date precision: day
Registry last updated2026-06-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Cancerunresolved
Interventions
Sacituzumab GovitecanDRUG · verified · RxNorm: sacituzumab govitecan
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Chinese University of Hong Konglead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06055465 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.